Use of phosphatase inhibitors for the treatment of neurodegenerative diseases
OwnerRoger Nitsch, Marlen Knobloch +2inventors
InventorsRoger Nitsch, Marlen Knobloch, Mélissa Farinelli, Isabelle Mansuy
Life of this patent
Estimating the term…
Abstract
Provided are novel a target and drugs in the treatment of neurological disorders related to amyloid beta pathology/amyloidosis. More specifically, the use of phosphatase inhibitors for the treatment of brain impairments mediated by Aβ-oligomers is described.
Claims19
A pharmaceutical composition for the treatment, amelioration, or prevention of a disorder associated with amyloid β (Aβ) pathology/amyloidosis, said composition comprising an inhibitor of protein phosphatase 1 (PP1), and optionally a pharmaceutically acceptable carrier.
A method of diagnosis of a disorder associated with amyloid β (Aβ) pathology/amyloidosis, said method comprising:
- (a) assaying a sample from a subject for PP1 gene product or activity;
- and
- (b) determining the level of PP1 gene product or activity, wherein an altered level compared to a control indicates the presence of the disorder.
A method of screening for or profiling of an inhibitor of PP1, said method comprising use of a non-human transgenic animal that expresses human APP carrying both familial Swedish and Arctic mutations.
Dependencies are inferred from the claim text.